BridgeBio Pharma (BBIO) Consolidated Net Income (2018 - 2026)
BridgeBio Pharma (BBIO) reported Consolidated Net Income of -$120.0 million for Q1 2026, up 1.83% on a YoY basis from -$117.9 million in Q1 2025, and up 38.32% sequentially from -$194.6 million in Q4 2025.
BridgeBio Pharma (BBIO) Consolidated Net Income (2018 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 9 years of Consolidated Net Income data on file, last reported at -$120.0 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 1.83% year-over-year to -$120.0 million; the trailing twelve-month figure through Mar 2026 stood at -$683.3 million (down 8.56% YoY), and the FY2025 full-year result was -$732.9 million, down 34.89% from the prior year.
- Consolidated Net Income climbed to -$120.0 million in Q1 2026, from -$194.6 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$35.0 million in Q1 2024 to a low of -$267.4 million in Q4 2024.
- A 5-year average of -$155.2 million and a median of -$164.3 million in 2024 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income soared 76.34% in 2024 and plunged 249.3% in 2025, its largest moves.
- Tracing BBIO's Consolidated Net Income over 5 years: stood at -$158.0 million in 2022, then declined by 28.04% to -$202.3 million in 2023, then plunged by 32.17% to -$267.4 million in 2024, then grew by 27.23% to -$194.6 million in 2025, then soared by 38.32% to -$120.0 million in 2026.
- Business Quant data shows BBIO's Consolidated Net Income at -$120.0 million in Q1 2026, -$194.6 million in Q4 2025, and -$184.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | -120.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.03 Mn |
| Dec 31, 2025 | -194.59 Mn |
| Sep 30, 2025 | -184.94 Mn |
| Jun 30, 2025 | -183.76 Mn |
| Mar 31, 2025 | -122.26 Mn |
| Dec 31, 2024 | -267.39 Mn |
| Sep 30, 2024 | -164.25 Mn |
| Jun 30, 2024 | -75.54 Mn |
| Mar 31, 2024 | -35.00 Mn |
| Dec 31, 2023 | -202.30 Mn |
| Sep 30, 2023 | -174.21 Mn |
| Jun 30, 2023 | -166.62 Mn |
| Mar 31, 2023 | -147.91 Mn |
| Dec 31, 2022 | -158.00 Mn |
| Sep 30, 2022 | -146.52 Mn |
| Jun 30, 2022 | -100.50 Mn |
| Mar 31, 2022 | -194.27 Mn |
| Dec 31, 2021 | -188.09 Mn |
| Sep 30, 2021 | -174.56 Mn |
| Jun 30, 2021 | -199.51 Mn |